Elite Journal of Medical Sciences. Volume 2 issue 7(2024), 49-57
https://epjournals.com/journals/EJMS

Role of G6PD Deficiency in Vaso-Occlusive Phenomena in Sickle Cell Disease

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Sickle cell disease (SCD) is a genetic hematological disorder characterized by the production of abnormal hemoglobin S (HbS), leading to the sickling of red blood cells (RBCs) and the occurrence of vaso-occlusive phenomena (VOP). Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common enzymatic disorder that can exacerbate the clinical manifestations of SCD, particularly by increasing oxidative stress and hemolysis. This review explores the multifaceted role of G6PD deficiency in the pathophysiology of VOP in SCD, focusing on its contribution to oxidative stress, endothelial dysfunction, and chronic inflammation, which collectively heighten the risk of vaso-occlusive crises. The impaired antioxidant defense resulting from G6PD deficiency leads to enhanced oxidative damage in RBCs, resulting in hemolysis and increased sickling. The release of free hemoglobin from lysed RBCs scavenges nitric oxide (NO), a critical vasodilator, promoting endothelial dysfunction and exacerbating the likelihood of vascular occlusion. Moreover, the inflammatory response induced by oxidative stress further compromises endothelial integrity, facilitating the adhesion of sickled cells and leukocytes to the vascular endothelium and triggering painful vaso-occlusive episodes.

Keywords*: sickle cell disease, vaso-occlusive crisis, G6PD deficiency, oxidative stress, hemolysis, endothelial dysfunction, therapeutic implications.*

Introduction

Sickle cell disease (SCD) is a hereditary hematological disorder characterized by the presence of hemoglobin S (HbS), resulting from a mutation in the β-globin gene. This mutation causes red blood cells (RBCs) to undergo polymerization under low oxygen conditions, leading to their deformation into a rigid, sickle shape. The sickling of RBCs impairs their ability to navigate the microvasculature, leading to vaso-occlusive phenomena (VOP) that manifest as painful crises, organ ischemia, and other significant complications. While the primary pathology of SCD lies in the abnormal structure of hemoglobin, various genetic and environmental factors can further exacerbate its clinical manifestations, one of which is glucose-6-phosphate dehydrogenase (G6PD) deficiency.[1-5] G6PD deficiency is one of the most common enzymatic disorders worldwide, particularly prevalent in individuals of African, Mediterranean, and Asian descent. The G6PD enzyme is crucial in the pentose phosphate pathway, which generates NADPH, an essential cofactor for maintaining the cellular redox state and protecting against oxidative stress. Individuals with G6PD deficiency have a reduced capacity to combat oxidative damage, making their RBCs more vulnerable to hemolysis. This increased hemolytic activity can significantly impact the clinical course of SCD, particularly in relation to the frequency and severity of vaso-occlusive crises.[6-10] The interplay between G6PD deficiency and SCD presents a complex relationship that influences the pathophysiology of VOP. In individuals with SCD and G6PD deficiency, oxidative

stress resulting from the impaired antioxidant defense system can exacerbate hemolysis and the production of sickle RBCs. The increased destruction of RBCs leads to a greater proportion of sickled cells in circulation, further heightening the risk of vaso-occlusive events. Understanding these mechanisms is crucial for optimizing management strategies and improving patient outcomes in this population.[11-13]

The relationship between oxidative stress and hemolysis in SCD is multifaceted. In individuals with G6PD deficiency, oxidative stress can damage RBC membranes, leading to their premature destruction. This process can release free hemoglobin into circulation, which scavenges nitric oxide (NO), a critical vasodilator that helps maintain vascular tone and prevent occlusion. The depletion of NO can lead to endothelial dysfunction, characterized by increased vascular resistance and impaired blood flow, further exacerbating the risk of vaso-occlusive crises in affected individuals.[14-16] Endothelial dysfunction is a key factor in the pathogenesis of VOP in SCD. G6PD deficiency-induced oxidative stress can impair endothelial cell function by promoting inflammation and increasing the expression of adhesion molecules. This dysregulation facilitates the adhesion of sickled RBCs and leukocytes to the vascular endothelium, promoting microvascular occlusion. The resultant inflammatory milieu further compromises endothelial integrity and amplifies the likelihood of vaso-occlusive events, creating a vicious cycle that exacerbates disease severity.[17-19] Chronic inflammation is another hallmark of SCD that is exacerbated by G6PD deficiency. The oxidative stress resulting from G6PD deficiency can activate various inflammatory pathways, leading to the release of pro-inflammatory cytokines and the recruitment of immune cells. This inflammatory response can further impair endothelial function and increase the risk of vaso-occlusive crises. Investigating the interplay between G6PD deficiency, oxidative stress, and inflammation is essential for understanding the complex pathophysiology of SCD.[20-22]

Additionally, the genetic background of individuals with SCD and G6PD deficiency can influence disease severity. The presence of other genetic modifiers, such as the sickle cell trait or other hemoglobinopathies, can interact with G6PD deficiency to further complicate the clinical picture. These interactions may affect the degree of hemolysis, oxidative stress, and the overall frequency of vaso-occlusive events. [23-25] The clinical implications of G6PD deficiency in the management of SCD are significant. Individuals with concurrent SCD and G6PD deficiency may experience more frequent and severe vaso-occlusive crises, leading to increased morbidity and healthcare costs. Moreover, recognizing the role of G6PD deficiency in SCD can help clinicians make informed decisions regarding the management of hemolytic episodes, pain crises, and potential complications. Patient education regarding the avoidance of oxidative stressors, such as certain medications and foods, is essential for minimizing the risk of hemolytic crises in this population.[26-28]

Mechanisms of G6PD Deficiency in Sickle Cell Disease

G6PD plays a crucial role in the pentose phosphate pathway, generating NADPH, which is essential for maintaining cellular redox balance and protecting cells from oxidative damage. In individuals with G6PD deficiency, the impaired production of NADPH leads to a decreased ability to regenerate reduced glutathione (GSH), a key antioxidant. This deficiency results in an increased accumulation of reactive oxygen species (ROS), which can cause oxidative damage to red blood cells (RBCs), proteins, and lipids. In the context of sickle cell disease (SCD), where oxidative stress is already heightened due to the presence of hemoglobin S (HbS), the exacerbation of

oxidative damage can lead to increased sickling of RBCs, further complicating the clinical course of the disease.[29-33] The oxidative stress induced by G6PD deficiency contributes to accelerated hemolysis of RBCs. The oxidative environment damages the RBC membrane, leading to premature cell lysis. In SCD, where hemolysis is a hallmark feature, G6PD deficiency can further intensify the destruction of erythrocytes. The resultant hemolysis releases free hemoglobin into circulation, which can scavenge nitric oxide (NO). This scavenging reduces the bioavailability of NO, impairing vasodilation and contributing to vascular complications, including vaso-occlusive crises (VOCs). The combination of sickle-shaped RBCs and a higher rate of hemolysis creates a more significant risk of vaso-occlusive events in individuals with both SCD and G6PD deficiency.[34-36] Endothelial cells are crucial for maintaining vascular homeostasis and regulating blood flow. G6PD deficiency-induced oxidative stress can compromise endothelial cell function, leading to endothelial dysfunction. Elevated levels of ROS can activate pro-inflammatory signaling pathways and increase the expression of adhesion molecules on endothelial cells. This activation facilitates the adhesion of sickled RBCs and leukocytes to the vascular endothelium, promoting microvascular obstruction and exacerbating the likelihood of VOCs. Furthermore, endothelial dysfunction can contribute to a pro-thrombotic state, increasing the risk of thromboembolic events in individuals with SCD and G6PD deficiency.[37-40]

The interplay between G6PD deficiency and the inflammatory response is a critical factor in the pathogenesis of VOCs in SCD. Oxidative stress can activate inflammatory pathways, leading to the release of pro-inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). This inflammatory milieu can further impair endothelial function and promote the adhesion of leukocytes to the endothelium. In individuals with SCD, chronic inflammation is already present, and the additional inflammatory burden from G6PD deficiency can create a vicious cycle that exacerbates endothelial dysfunction and increases the frequency and severity of VOCs.[41-44] The genetic background of individuals with SCD and G6PD deficiency can influence disease severity and clinical outcomes. Variants in other genes, such as those encoding for various hemoglobinopathies or inflammation-related proteins, can interact with G6PD deficiency and modify the overall disease phenotype. For example, individuals with both sickle cell trait and G6PD deficiency may experience different clinical manifestations compared to those with only one condition.[45-47] The combination of oxidative stress, hemolysis, and endothelial dysfunction resulting from G6PD deficiency contributes to an increased frequency of vaso-occlusive crises in individuals with SCD. The additional oxidative burden leads to a greater proportion of sickled RBCs in circulation, which can further impede blood flow and promote microvascular occlusion. As a result, individuals with both SCD and G6PD deficiency may experience more frequent and severe episodes of pain and other complications associated with VOCs.[48-51]

In individuals with G6PD deficiency, the increased hemolysis and oxidative stress can impair erythropoiesis, the process of producing new RBCs. The bone marrow microenvironment may be altered by the inflammatory and oxidative stress conditions, affecting the differentiation and proliferation of erythroid progenitor cells. This disruption can lead to ineffective erythropoiesis, exacerbating anemia and increasing the risk of further complications in SCD. Understanding the impact of G6PD deficiency on erythropoiesis is essential for addressing the overall health of individuals with SCD.[52-56] The mechanisms through which G6PD deficiency exacerbates vaso-occlusive phenomena in SCD have significant clinical implications. Individuals with concurrent

G6PD deficiency may require more vigilant monitoring and management strategies to mitigate the effects of oxidative stress and hemolysis. Healthcare providers should consider the presence of G6PD deficiency when evaluating patients with SCD, as this knowledge can inform treatment decisions and enhance patient education regarding lifestyle modifications to reduce oxidative stressors.[57-59] Targeting oxidative stress and inflammation may provide therapeutic avenues for managing VOC in individuals with SCD and G6PD deficiency. Antioxidant therapies, such as N-acetylcysteine (NAC) or other compounds that enhance the body's antioxidant capacity, could potentially reduce oxidative damage and improve clinical outcomes. Additionally, anti-inflammatory agents may help mitigate the inflammatory response associated with G6PD deficiency, improving endothelial function and reducing the risk of VOC.[60-65]

Conclusion

Glucose-6-phosphate dehydrogenase (G6PD) deficiency plays a significant role in exacerbating vaso-occlusive phenomena in sickle cell disease (SCD). The interplay between oxidative stress, increased hemolysis, endothelial dysfunction, and chronic inflammation contributes to the heightened frequency and severity of vaso-occlusive crises in individuals with both conditions. G6PD deficiency impairs the antioxidant defense mechanisms of red blood cells, leading to oxidative damage, premature hemolysis, and a subsequent decrease in the bioavailability of nitric oxide, which is critical for vascular health. The implications of G6PD deficiency extend beyond the immediate pathophysiological effects; they also inform clinical management strategies for SCD. Healthcare providers must be aware of the presence of G6PD deficiency in their patients with SCD, as this knowledge can guide treatment decisions, improve patient education, and optimize management of vaso-occlusive crises. Additionally, targeted therapeutic approaches aimed at reducing oxidative stress and inflammation may offer new avenues for improving clinical outcomes in individuals with SCD and G6PD deficiency.

References

1. Alenzi FQ, AlShaya DS. Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Sciences. 2019;26(7):1377-1384.
2. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annual review of genomics and human genetics. 2018;19(1):113-147.
3. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
4. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
5. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
6. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
7. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
8. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.

9. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
10. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
11. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circulation research. 2007 Sep 28;101(7):654-662.
12. Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: in physiology and in disease states. American journal of biomedical science & research. 2022;15(2):153.
13. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
14. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
15. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
21. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
25. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):67-80.
26. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).

27. Vilas-Boas W, Cerqueira BA, Zanette AM, Reis MG, Barral-Netto M, Goncalves MS. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Annals of hematology. 2010; 89:877-882.
28. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.
29. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
30. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
31. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
32. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
33. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
34. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
35. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
36. Tsikas D. Does the inhibitory action of asymmetric dimethylarginine (ADMA) on the endothelial nitric oxide synthase activity explain its importance in the cardiovascular system? The ADMA paradox. Journal of Controversies in Biomedical Research. 2017;3(1):16-22.
37. Martins R, Knapp S. Heme and hemolysis in innate immunity: adding insult to injury. Current opinion in immunology. 2018; 50:14-20.
38. Wu G, Meininger CJ, McNeal CJ, Bazer FW, Rhoads JM. Role of L-arginine in nitric oxide synthesis and health in humans. Amino acids in nutrition and health: Amino acids in gene expression, metabolic regulation, and exercising performance. 2021:167-87.
39. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
40. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of

agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
41. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
42. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
43. Roberts BW, Mitchell J, Kilgannon JH, Chansky ME, Trzeciak S. Nitric oxide donor agents for the treatment of ischemia/reperfusion injury in human subjects: a systematic review. Shock. 2013;39(3):229-339.
44. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
45. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.
46. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
47. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
48. Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annual review of pharmacology and toxicology. 2023;63(1):585-615.
49. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024;103(2):e36898.
50. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
51. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
52. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
53. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
54. Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, Golab J. Myeloid cell-derived arginase in cancer immune response. Frontiers in immunology. 2020; 11:938.
55. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
56. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
57. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
58. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.

59. Bontempo P, Capasso L, De Masi L, Nebbioso A, Rigano D. Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future Directions. Nutrients. 2024;16(15):2399.
60. Cao M, Zhao Y, He H, Yue R, Pan L, Hu H, Ren Y, Qin Q, Yi X, Yin T, Ma L. New applications of HBOC-201: a 25-year review of the literature. Frontiers in Medicine. 2021; 8:794561.
61. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal. 2003;3(4):215-226.
62. Obeagu EI. Redox Signaling and Vaso-Occlusive Crisis in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 26-35
63. Obeagu EI. Hypoxia-Induced Signaling in the Pathogenesis of Vaso-Occlusive Crisis. *Elite Journal of Haematology, 2024; 2(7):* 36-43
64. Obeagu EI. Neurovascular Regulation and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 41-48
65. Obeagu EI. Bone Marrow Microenvironment and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 49-56